Brief: Eloxx Pharmaceuticals Announces Final Data Assessment From Phase 2 Combination Clinical Trial Of ELX-02

Eloxx Pharmaceuticals

14/06/2023 22:31

June 14 (Reuters) - Eloxx Pharmaceuticals Inc  ELOX.O :
    * ELOXX PHARMACEUTICALS ANNOUNCES FINAL DATA ASSESSMENT FROM
PHASE
2 COMBINATION CLINICAL TRIAL OF ELX-02 IN CLASS 1 CYSTIC
FIBROSIS (CF) PATIENTS
    * ELOXX PHARMACEUTICALS INC - ELX-02 WAS GENERALLY WELL
TOLERATED
IN TRIAL, WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS NOTED
    * ELOXX PHARMACEUTICALS INC- ELX-02 TRIAL DEMONSTRATED
CLINICALLY
RELEVANT IMPROVEMENT IN PERCENT PPFEV1 BASED ON FINAL DATA
ASSESSMENT

Source text for Eikon:  ID:nGNX4GlFjN 
Further company coverage:  ELOX.O 

 ((Reuters.Briefs@thomsonreuters.com;))